Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$49.35
Change (%) Stock is Up 1.40 (2.92%)
Volume492,747
Data as of 08/16/18 11:51 a.m. ET
Refresh quote
Featured Events
Webcast ImageWebcast
Global Blood Therapeutics Inc at 2018 Wedbush PacGrow Healthcare Conference (Replay)
08/14/18 at 10:20 a.m. ET
Global Blood Therapeutics Inc at 2018 Wedbush PacGrow Healthcare Conference
Tuesday, August 14, 2018 10:20 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Presentation
There are currently no items available.
Recent NewsMore >>
DateTitle 
08/07/18GBT Announces Participation at the 2018 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 14 at 10:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deli... 
Printer Friendly Version
08/03/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on August 1, 2018, the compensation committee of the Company’s board of directors granted two new employees options to purchase an aggregate of 2,500 shares of the Company’s common stock with a per share exercise price of $43.15, the closing trading price on the grant date, and restricted stock units for an aggregate of 1,650 shares of the Company’s common st... 
Printer Friendly Version
08/02/18GBT Reports Recent Business Progress and Provides Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the second quarter ended June 30, 2018. "We continue to advance our voxelotor clinical development program with the goal of bringing this potentially transformative treatment to the sickle cell disease, or SCD, community as soon as possible,” said Ted W. Love, M.D., president and chief executive officer of GBT. “As part o... 
Printer Friendly Version
07/03/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that, on July 2, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 6,500 shares of the Company’s common stock with a per share exercise price of $42.90, the closing trading price on the grant date, and restricted stock units for an aggregate of 4,300 shares of the Company’s common stoc... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.